New Products

Blockbuster to be? Novartis snags a major win as FDA OKs a top PhIII drug — will a pricing controversy follow?

After racking up a large batch of positive data demonstrating its ability to slow the rate of disease progression, Novartis today toasted an FDA approval of their S1P multiple sclerosis drug siponimod, soon to hit the market as Mayzent.

By most accounts, this is a blockbuster to be. And it also could be a blockbuster killer.

EvaluatePharma pegged 2024 sales of this drug at $1.3 billion, making it an important part of Novartis’ late-stage pipeline and a checkmark in the win column for development chief John Tsai and CEO Vas Narasimhan, who handed him the job when Narasimhan moved up in the world.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->